Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients.

[1]  F. Negro,et al.  EASL Clinical Practice Guidelines on hepatitis E virus infection. , 2018, Journal of hepatology.

[2]  D. Hesselink,et al.  Dosing ribavirin in hepatitis E‐infected solid organ transplant recipients , 2018, Pharmacological research.

[3]  R. Aggarwal,et al.  Hepatitis E Virus Infection , 2014, Clinical Microbiology Reviews.

[4]  J. Izopet,et al.  When Should Ribavirin Be Started to Treat Hepatitis E Virus Infection in Transplant Patients? , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  J. Izopet,et al.  Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy , 2015, Antimicrobial Agents and Chemotherapy.

[6]  L. Rostaing,et al.  An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients , 2015, Transplantation.

[7]  M. Manns,et al.  A mutation in the hepatitis E virus RNA polymerase promotes its replication and associates with ribavirin treatment failure in organ transplant recipients. , 2014, Gastroenterology.

[8]  J. Dumortier,et al.  Ribavirin for chronic hepatitis E virus infection in transplant recipients. , 2014, The New England journal of medicine.

[9]  M. Manns,et al.  Ribavirin treatment of acute and chronic hepatitis E: a single‐centre experience , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[10]  J. Izopet,et al.  Genotype 3 Diversity and Quantification of Hepatitis E Virus RNA , 2011, Journal of Clinical Microbiology.

[11]  L. Rostaing,et al.  Protracted fecal shedding of HEV during ribavirin therapy predicts treatment relapse. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.